Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CTSD | P07339 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL626056 | 0.86 | MEN1 (0.54) | SMN1; SMN2NPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL627825 | 0.86 | KMT2A (0.52) | SMN1; SMN2HTTALDH1A1MEN1KMT2A | |
| SCHEMBL8306088 | 0.81 | HDAC6 (0.48) | SMN1; SMN2CYP3A4ALDH1A1MEN1KMT2A | |
| SCHEMBL653044 | 0.81 | CYP1A2 (0.50) | SMN1; SMN2NPC1ABCG2CYP1A2CYP3A4 | |
| SCHEMBL627311 | 0.80 | MEN1 (0.51) | SMN1; SMN2NPC1GAAHTTALDH1A1 | |
| SCHEMBL627865 | 0.80 | ABCG2 (0.57) | SMN1; SMN2NPC1ABCG2GAAALDH1A1 | |
| SCHEMBL4319731 | 0.79 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1ABCG2CYP1A2CYP3A4 | |
| SCHEMBL4319728 | 0.79 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1ABCG2CYP1A2CYP3A4 | |
| SCHEMBL628220 | 0.79 | NPC1 (0.50) | SMN1; SMN2NPC1CYP3A4GAAALDH1A1 | |
| SCHEMBL6254946 | 0.77 | NPC1 (0.53) | SMN1; SMN2NPC1GAAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4648630-B2 | — | — | 2011-03-09 | — | — | JP | claimed |
| JP-2005530711-A | — | — | 2005-10-13 | — | — | JP | claimed |
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | claimed |
| EP-1487804-A2 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | claimed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | claimed |
| WO-2003078403-A2 | DERIVES D’AMINOINDAZOLES COMME INHIBITEURS DE PROTEINE-KINASE | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | claimed |
| EP-1506176-B1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PFIZER ITALIA SRL (IT) | 2013-04-24 | — | — | EP | disclosed |
| EP-1820503-B1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA SRL (IT) | 2012-02-22 | — | — | EP | disclosed |
| EP-1432416-B1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER ITALIA SRL (IT) | 2011-01-19 | — | — | EP | disclosed |
| US-7632854-B2 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2009-12-15 | — | — | US | disclosed |
| US-7511136-B2 | Aminoindazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-03-31 | — | — | US | disclosed |
| EP-1820503-A2 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | Pfizer Italia S.r.l. (IT) | 2007-08-22 | — | — | EP | disclosed |
| US-20060106083-A1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2006-05-18 | — | — | US | disclosed |
| EP-1487804-A2 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | disclosed |
| US-20040254177-A1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2004-12-16 | — | — | US | disclosed |
| EP-1432416-A1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pharmacia Italia S.p.A. (IT) | 2004-06-30 | — | — | EP | disclosed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | disclosed |
| WO-2003097610-A1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003078403-A2 | DERIVES D’AMINOINDAZOLES COMME INHIBITEURS DE PROTEINE-KINASE | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003028720-A1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106083-A1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K15, MAP3K3, MAP3K20 | SMN1; SMN2 2900/4885NPC1 2921/4885ABCG2 2448/4885 |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | CYP2C8, NR0B2, NR2C2 | SMN1; SMN2 3494/4885NPC1 1463/4885ABCG2 293/4885 |
| US-20040254177-A1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | MAP3K15, MAP3K3, MAP3K5 | SMN1; SMN2 2750/4885NPC1 2870/4885ABCG2 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.